FDA Grants Fast Track to Onvansertib in First-Line RAS-Mutated Colorectal Cancer
CRDF sits 17% above its 52-week low of $0.711 on light trading volume (0.3× avg).
Summary
The FDA granted Fast Track designation to onvansertib plus FOLFIRI/bevacizumab for first-line KRAS- or NRAS-mutated metastatic colorectal cancer, a setting with no specifically approved therapy. The designation rests on the randomized Phase 2 CRDF-004 data: the proposed 30 mg Phase 3 regimen posted a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone, and median progression-free survival in the 30 mg arm had not been reached as of September 28, 2026, versus roughly 11 months in the standard-of-care arms. Fast Track opens more frequent FDA interaction and eligibility for rolling review and, if criteria are met, Accelerated Approval and Priority Review — meaningful for a company whose Q3 10-Q showed $33.8 million in cash and investments funding operations only to the end of Q3 2027 with going-concern doubt. It follows October's orphan designation in CMML and a November orphan designation in small cell lung cancer, building a regulatory momentum narrative around the lead asset. The next concrete step is advancing onvansertib into the planned registrational trial in first-line RAS-mutated mCRC.
At the time of this announcement, CRDF was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.5M. The 52-week trading range was $0.71 to $3.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.